MANGALAM
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Mangalam Drugs And Organics Says Awarded Grant By Medicines For Malaria Venture
Aug 26 (Reuters) - Mangalam Drugs and Organics Ltd MADR.NS:
MANGALAM DRUGS AND ORGANICS - AWARDED GRANT BY MEDICINES FOR MALARIA VENTURE
MANGALAM DRUGS - GRANT AMOUNTS TO $274,800, DESIGNATED FOR RESEARCH OF PYRONARIDINE
MANGALAM DRUGS AND ORGANICS - PLANS TO COMMERCIALIZE PRODUCT BY END OF 2024
Source text for Eikon: ID:nBSE7DgMP5
Further company coverage: MADR.NS
(([email protected];))
Aug 26 (Reuters) - Mangalam Drugs and Organics Ltd MADR.NS:
MANGALAM DRUGS AND ORGANICS - AWARDED GRANT BY MEDICINES FOR MALARIA VENTURE
MANGALAM DRUGS - GRANT AMOUNTS TO $274,800, DESIGNATED FOR RESEARCH OF PYRONARIDINE
MANGALAM DRUGS AND ORGANICS - PLANS TO COMMERCIALIZE PRODUCT BY END OF 2024
Source text for Eikon: ID:nBSE7DgMP5
Further company coverage: MADR.NS
(([email protected];))
India's Mangalam Drugs and Organics up on expanding anti-malaria portfolio
** Shares of Mangalam Drugs And Organics MADR.NS rise 6.7% to 121.7 rupees
** The pharmaceutical co said on Tuesday it is expanding its anti-malaria API portfolio with the introduction of Pyronaridine
** More than 226,000 shares change hands, 2.2x its 30-day avg
** Stock up 24% so far this year, eyes best yearly gain since 2020
(Reporting by Ashna Teresa Britto in Bengaluru)
(([email protected] ; ( +91 8078332441))
** Shares of Mangalam Drugs And Organics MADR.NS rise 6.7% to 121.7 rupees
** The pharmaceutical co said on Tuesday it is expanding its anti-malaria API portfolio with the introduction of Pyronaridine
** More than 226,000 shares change hands, 2.2x its 30-day avg
** Stock up 24% so far this year, eyes best yearly gain since 2020
(Reporting by Ashna Teresa Britto in Bengaluru)
(([email protected] ; ( +91 8078332441))
Mangalam Drugs And Organics Approved Scheme Of Merger By Absorption Of Mangalam Laboratories, Shri Jb Pharma With Co
June 18 (Reuters) - Mangalam Drugs and Organics Ltd MADR.NS:
APPROVED SCHEME OF MERGER BY ABSORPTION OF MANGALAM LABORATORIES, SHRI JB PHARMA WITH MANGALAM DRUGS AND ORGANICS
Source text for Eikon: ID:nBSE711X9P
Further company coverage: MADR.NS
(([email protected];;))
June 18 (Reuters) - Mangalam Drugs and Organics Ltd MADR.NS:
APPROVED SCHEME OF MERGER BY ABSORPTION OF MANGALAM LABORATORIES, SHRI JB PHARMA WITH MANGALAM DRUGS AND ORGANICS
Source text for Eikon: ID:nBSE711X9P
Further company coverage: MADR.NS
(([email protected];;))
India's Mangalam Drugs And Organics Posts Sept-Quarter Net Loss
Nov 8 (Reuters) - Mangalam Drugs and Organics Ltd MADR.NS:
INDIA'S MANGALAM DRUGS AND ORGANICS SEPT-QUARTER NET LOSS 35.6 MILLION RUPEES VERSUS PROFIT 22.3 MILLION RUPEES
MANGALAM DRUGS AND ORGANICS SEPT-QUARTER NET SALES FROM OPERATIONS 813.7 MILLION RUPEES VERSUS 1.08 BILLION RUPEES
Source text for Eikon: ID:nBSE9wg0mg
Further company coverage: MADR.NS
(([email protected];))
Nov 8 (Reuters) - Mangalam Drugs and Organics Ltd MADR.NS:
INDIA'S MANGALAM DRUGS AND ORGANICS SEPT-QUARTER NET LOSS 35.6 MILLION RUPEES VERSUS PROFIT 22.3 MILLION RUPEES
MANGALAM DRUGS AND ORGANICS SEPT-QUARTER NET SALES FROM OPERATIONS 813.7 MILLION RUPEES VERSUS 1.08 BILLION RUPEES
Source text for Eikon: ID:nBSE9wg0mg
Further company coverage: MADR.NS
(([email protected];))
Mangalam Drugs And Organics Says Govardhan Murlidhar Dhoot To Continue As MD
March 29 (Reuters) - Mangalam Drugs and Organics Ltd MADR.NS:
GOVARDHAN MURLIDHAR DHOOT TO CONTINUE AS MD
Source text for Eikon: ID:nBSE95zsgY
Further company coverage: MADR.NS
(([email protected];))
March 29 (Reuters) - Mangalam Drugs and Organics Ltd MADR.NS:
GOVARDHAN MURLIDHAR DHOOT TO CONTINUE AS MD
Source text for Eikon: ID:nBSE95zsgY
Further company coverage: MADR.NS
(([email protected];))
Events:
Dividend
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Mangalam Drugs&Org. do?
Mangalam Drugs and Organics Limited, an India-based company, specializes in manufacturing various chemicals including active pharma ingredients, perfumery, disperse dye intermediates, bulk drugs, and bulk drugs intermediates.
Who are the competitors of Mangalam Drugs&Org.?
Mangalam Drugs&Org. major competitors are Tyche Inds, Smruthi Organics, Bal Pharma, Lasa Supergenerics, SMS Lifesciences, Everest Organics, Nectar Lifesciences. Market Cap of Mangalam Drugs&Org. is ₹128 Crs. While the median market cap of its peers are ₹160 Crs.
Is Mangalam Drugs&Org. financially stable compared to its competitors?
Mangalam Drugs&Org. seems to be less financially stable compared to its competitors. Altman Z score of Mangalam Drugs&Org. is 2.06 and is ranked 5 out of its 8 competitors.
Does Mangalam Drugs&Org. pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Mangalam Drugs&Org. latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Mangalam Drugs&Org. allocated its funds?
Companies resources are majorly tied in miscellaneous assets
How strong is Mangalam Drugs&Org. balance sheet?
Balance sheet of Mangalam Drugs&Org. is moderately strong, But short term working capital might become an issue for this company.
Is the profitablity of Mangalam Drugs&Org. improving?
The profit is oscillating. The profit of Mangalam Drugs&Org. is ₹6.72 Crs for TTM, -₹9.07 Crs for Mar 2024 and ₹1.27 Crs for Mar 2023.
Is the debt of Mangalam Drugs&Org. increasing or decreasing?
The net debt of Mangalam Drugs&Org. is decreasing. Latest net debt of Mangalam Drugs&Org. is ₹78.58 Crs as of Mar-25. This is less than Mar-24 when it was ₹92.79 Crs.
Is Mangalam Drugs&Org. stock expensive?
Mangalam Drugs&Org. is expensive when considering the PE ratio, however latest EV/EBIDTA is < 3 yr avg EV/EBIDTA. Latest PE of Mangalam Drugs&Org. is 19.06, while 3 year average PE is 16.01. Also latest EV/EBITDA of Mangalam Drugs&Org. is 5.77 while 3yr average is 11.66.
Has the share price of Mangalam Drugs&Org. grown faster than its competition?
Mangalam Drugs&Org. has given lower returns compared to its competitors. Mangalam Drugs&Org. has grown at ~-3.75% over the last 7yrs while peers have grown at a median rate of 8.12%
Is the promoter bullish about Mangalam Drugs&Org.?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Mangalam Drugs&Org. is 50.3% and last quarter promoter holding is 50.3%.
Are mutual funds buying/selling Mangalam Drugs&Org.?
There is Insufficient data to gauge this.